
Sign up to save your podcasts
Or


🚨 Real-World vs RCT? Only 1 in 3 patients with AMI-related cardiogenic shock in Japan met the 🔬 DanGer trial criteria for Impella use. The J-PVAD registry (🇯🇵, n=3975) reveals a stark ⚖️ reality: eligibility matters, and survival varies!
🫀 Time to align practice with precision.
📖 Read the full European Heart Journal study for clinical pearls and caveats. #Impella #CardiogenicShock #DanGer #JPVAD #EHJ #MCS #RCTvsRealWorld
By Dr RR Baliga, MD, MBA5
66 ratings
🚨 Real-World vs RCT? Only 1 in 3 patients with AMI-related cardiogenic shock in Japan met the 🔬 DanGer trial criteria for Impella use. The J-PVAD registry (🇯🇵, n=3975) reveals a stark ⚖️ reality: eligibility matters, and survival varies!
🫀 Time to align practice with precision.
📖 Read the full European Heart Journal study for clinical pearls and caveats. #Impella #CardiogenicShock #DanGer #JPVAD #EHJ #MCS #RCTvsRealWorld

892 Listeners

3,376 Listeners

21,475 Listeners